Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8431 to 8445 of 8898 results

  1. Synergo for non-muscle-invasive bladder cancer (MIB226)

    This advice has been updated and replaced by NICE healthtech guidance 601.

  2. AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)

    This advice has been updated and replaced by NICE healthtech guidance 607.

  3. 3C Patch System for treating diabetic foot ulcers (MIB230)

    This advice has been updated and replaced by NICE Healthtech guidance 615.

  4. KardiaMobile for the ambulatory detection of atrial fibrillation (MIB232)

    This advice has been updated and replaced by NICE healthtech guidance 606.

  5. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

  6. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

  7. Artificial intelligence for analysing chest X-ray images (MIB292)

    This medtech innovation briefing has been updated and replaced by HealthTech guidance 696

  8. Kurin Lock for blood culture collection (MIB297)

    This medtech innovation briefing (MIB) has been replaced by NICE healthtech guidance 715.

  9. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  10. Ventripoint Medical System Plus for measuring heart volume and function (MIB310)

    February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.